Skip to main content

Synchrony Financial

For the period ended Mar 31, 2025. Filed Apr 24, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed Apr 24, 2025

SYF$73.22-0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the three months ended March 31, 2025, certain of our directors and executive officers adopted trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). Information regarding these Rule 10b5-1 trading arrangements is presented in the table below. No other directors or officers of the Company adopted modified or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each such term is defined in item 408(a) of Regulation S-K, during the three months ended March 31, 2025.

NameTitleAction Taken (Adoption or Termination Date)Duration(1)Aggregate Number of Securities to be Sold or Gifted(2)
Arthur W. CovielloDirectorAdoption (02/17/2025)2/17/2025 - 3/31/202618,000
Jonathan S. MothnerExecutive Vice President, Chief Risk and Legal OfficerAdoption (01/30/2025)1/30/2025 - 1/30/202643,439
Jeffrey G. NaylorDirectorAdoption (01/30/2025)1/30/2025 - 12/31/202530,000

(1)Pursuant to the terms of each plan and subject to compliance with Rule 10b5-1, each plan may terminate at an earlier date under certain circumstances, including if all trades are executed or all orders related to the trades under the relevant plan expire.

(2)The trading plans for Messrs. Coviello and Mothner include gifts of 6,000 and 2,800 shares, respectively.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.